Spyre Therapeutics (SYRE) director logs 5,000-share option exercise and 23,000-share sale
Rhea-AI Filing Summary
Spyre Therapeutics, Inc. director Jeffrey W. Albers reported an option exercise and related share sales on August 7, 2026. He exercised stock options covering 5,000 shares of common stock at a $10.39 exercise price and retained options on 45,000 shares. On the same date, he reported sales totaling 23,000 shares of common stock at weighted average prices slightly above $104 per share, including sales by Sessions LLC reported as indirect ownership. All transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026.
Positive
- None.
Negative
- None.
Insights
Analyzing...
Insider Trade Summary 10b5-1
Exercise and sale activity reported; no spread calculated
Exercise and Sale
5 txns
Insider
Albers Jeffrey W.
Role
Director
Sold
23,000 shs ($2.40M)
Approx. gross sale proceeds
$2.40M
Approx. exercise cost
$52K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F1, F5 | 5,000 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 5,000 | $10.39 | $52K |
| Sale | Common Stock F1, F2 | 5,000 | $104.47 | $522K |
| Sale | Common Stock F1, F3 | 8,000 | $104.38 | $835K |
| Sale | Common Stock F1, F4 | 10,000 | $104.68 | $1.05M |
Holdings After Transaction:
Stock Option (Right to Buy) — 45,000 shares (Direct);
Common Stock — 0 shares (Direct);
Common Stock — 9,360 shares (Indirect, By Sessions LLC)
Footnotes (5)
- F1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026.
- F2. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $103.59 to $105.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
- F3. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $103.52 to $105.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F4. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $103.60 to $106.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F5. This option represents a right to purchase 50,000 shares of the Issuer's common stock, which vest and become exercisable in 36 equal monthly installments beginning on November 22, 2023 until such time as the option is 100% vested, subject to the Reporting Person's continuous service with the Issuer at each vesting date.
Key Figures
Options exercised: 5,000 shares
Exercise price: $10.39 per share
Shares sold (total): 23,000 shares
+4 more
7 metrics
Options exercised
5,000 shares
Stock option for common stock exercised on August 7, 2026
Exercise price
$10.39 per share
Exercise price of stock option covering 5,000 shares
Shares sold (total)
23,000 shares
Common stock sales on August 7, 2026, direct and indirect
Direct sale price
$104.47 per share
Weighted average price for 5,000 directly held shares sold
Indirect sale prices
$104.38 and $104.68 per share
Weighted average prices for 8,000 and 10,000 shares sold by Sessions LLC
Options remaining
45,000 shares
Stock option shares remaining after 5,000-share exercise
10b5-1 plan adoption date
April 16, 2026
Date of Rule 10b5-1 trading plan governing these transactions
Key Terms
Rule 10b5-1 trading plan, weighted average price, indirect, Stock Option (Right to Buy), +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"This transaction was executed pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported above is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
indirect financial
"ownership_type": "indirect","ownership_code": "I""
Stock Option (Right to Buy) financial
"security_title": "Stock Option (Right to Buy)""
vest and become exercisable financial
"shares of the Issuer's common stock, which vest and become exercisable in 36 equal"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did SYRE director Jeffrey W. Albers report in this Form 4?
Jeffrey W. Albers reported exercising stock options for 5,000 shares of Spyre Therapeutics common stock and selling 23,000 shares, including indirect sales through Sessions LLC, all dated August 7, 2026 under a trading plan.
What option exercise did Albers disclose for Spyre Therapeutics (SYRE)?
He disclosed exercising a stock option for 5,000 shares of Spyre Therapeutics common stock at an exercise price of $10.39 per share, leaving 45,000 option shares remaining exercisable under the same option grant.